HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

antagomir-148a

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - Antagomirs: 693
        antagomir-148a: 3

Experts

1.	Deng, Jun: 1 article (01/2020)
2.	Li, Guanhua: 1 article (01/2020)
3.	Li, Jun: 1 article (01/2020)
4.	Liao, Zhuojun: 1 article (01/2020)
5.	Liu, Lu: 1 article (01/2020)
6.	Meng, Yao: 1 article (01/2020)
7.	Shen, Nan: 1 article (01/2020)
8.	Sun, Qing: 1 article (01/2020)
9.	Wu, Li: 1 article (01/2020)
10.	Ye, Zhizhong: 1 article (01/2020)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2020 - "Furthermore, we found that miR-148a increased in monocytes from patients with psoriasis, and miR-148a deficiency or intradermal injection of antagomir-148a immensely alleviated the development of psoriasis-like symptoms in a psoriasis-like mouse model. "
2.	Inflammation (Inflammations) 01/01/2018 - "Thus, antagomir-148a might qualify as an effective drug to selectively deplete pro-inflammatory Th1 cells of chronic inflammation without affecting the protective immunological memory." 01/01/2018 - "The effect of antagomir-148a was selective for chronic inflammation. "
3.	Colitis 01/01/2018 - "In the murine model of transfer colitis, antagomir-148a treatment reduced the number of pro-inflammatory Th1 cells in the colon of colitic mice by 50% and inhibited miR-148a expression by 71% in the remaining Th1 cells. "
4.	Bone Resorption 06/01/2015 - "Our results demonstrated that D-Asp8 could facilitate the enrichment of antagomir-148a and the subsequent down-regulation of miR-148a in osteoclasts in vivo, resulting in reduced bone resorption and attenuated deterioration of trabecular architecture in osteoporotic mice. " 06/01/2015 - "Considering that the eight repeating sequences of aspartate (D-Asp8) could preferably bind to highly crystallized hydroxyapatite, we developed a targeting system by conjugating D-Asp8 peptide with liposome for delivering microRNA modulators specifically to bone resorption surfaces and subsequently encapsulated antagomir-148a (a microRNA modulator suppressing the osteoclastogenic miR-148a), i.e. "

Related Drugs and Biologics

1.	MicroRNAs (MicroRNA)
2.	Durapatite (Hydroxylapatite)
3.	Peptides (Polypeptides)
4.	Liposomes (Liposome)
5.	Aspartic Acid (Aspartate)

Related Therapies and Procedures

1.	Intradermal Injections